Abivax S.A. (ABVX) Form 6-K — May 22, 2026
Abivax reported Q1 2026 financial results showing a net loss of €48.5 million, a slight improvement from the €52.4 million loss in the same period last year, driven by a €8.0 million financial gain and controlled operating expenses. The company maintains a strong balance sheet with €491.6 million in cash, cash equivalents, and short-term investments, providing a projected cash runway into the fourth quarter of 2027. The filing highlights positive interim data from Study 108, a long-term open-label extension trial of obefazimod in ulcerative colitis patients.
Key figures
- Revenue
- 1300000
- Cash Position
- 491600000
- Ga Expenses
- 6300000
- Rd Expenses
- 49500000
- Financial Gain
- 8000000
- Ads Offering Price
- 111.57
- Sales Marketing Expenses
- 1700000
- Ads Issued For Royalty Repurchase
- 403347
- Royalty Certificate Repurchase Cost
- 90000000
- Royalty Certificate Repurchase Expense
- 43000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.